Stock AnalizImmunome Inc. IMNM
Biotechnology: Pharmaceutical Preparations · IPO 2020 · data as of November 13, 2026
Immunome Inc. (IMNM) is a healthcare company listed in the US with a market value of about $2.2B. In fiscal year 2025 it had revenue of $7M and net income of -$212M, a net margin of -3060.0%.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -89%.
Score: 0.4 / 5
Checks passed
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 7 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $7M | $9M | $14M | — | — | — | — |
| Net income | -$212M | -$293M | -$107M | -$37M | -$25M | -$18M | -$10M |
| Free cash flow | -$201M | -$118M | -$8M | -$29M | -$18M | -$13M | -$10M |
| EPS (diluted) | $-2.43 | $-5.00 | $-5.38 | $-3.09 | $-2.14 | $-5.26 | $-9.55 |
| Net margin | -3060.0% | -3240.4% | -761.9% | — | — | — | — |
| ROIC | -27.7% | -129.9% | -71.2% | -175.0% | -40.9% | -23.2% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 15 analysts is $35.13, 87% above the current price; targets range from $23.00 to $40.00; the consensus rating is “Strong buy”; expected EPS is $-2.50 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Immunome pay a dividend?
Not currently.
Is Immunome a good stock to buy?
We do not give buy or sell advice. Immunome scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.